5,543 results match your criteria Bullous Pemphigoid


Immunoglobulin M bullous pemphigoid: An enigma.

JAAD Case Rep 2020 Jun 21;6(6):518-520. Epub 2020 Apr 21.

Department of Dermatology, University of Groningen, University Medical Center Groningen, Center for Blistering Diseases, Groningen, Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.008DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256243PMC

A rare association of bullous pemphigoid with mycosis fungoides and Sézary syndrome.

JAAD Case Rep 2020 Jun 1;6(6):486-488. Epub 2020 May 1.

Dr. Phillip Frost Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, Florida.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.024DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256241PMC

Two infants with blistering rashes originating on acral sites as a presenting sign of infantile bullous pemphigoid.

JAAD Case Rep 2020 Jun 18;6(6):473-475. Epub 2020 Apr 18.

Department of Dermatology, University of Michigan, Ann Arbor, Michigan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.04.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7256229PMC

Young-onset Amyotrophic Lateral Sclerosis with Rare Skin Manifestation: Case Report and Literature Review.

Cureus 2020 Apr 27;12(4):e7844. Epub 2020 Apr 27.

Medicine, Dow University of Health Sciences, Karachi, PAK.

Amyotrophic lateral sclerosis (ALS) is one of the most common motor neuron diseases (MND), which presents as muscle weakness, atrophy, spasticity, and, in extreme cases, may result in death due to respiratory failure. ALS has been reported with dermatological conditions such as bullous pemphigoid and decreased collagen. Hyperpigmentation usually occurs due to underlying adrenal or metabolic disorder, but no case of hyperpigmentation has been associated with MND. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7759/cureus.7844DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7253073PMC

Bullous skin disease patients in a high-epidemic COVID-19 area, Bergamo, Italy.

Br J Dermatol 2020 Jun 1. Epub 2020 Jun 1.

Dermatology Unit, ASST Papa Giovanni XXIII Hospital, Lombardy, Bergamo, Italy.

Bullous pemphigoid (BP) and pemphigus vulgaris (PV) are blistering disorders associated with barrier disruption, immune dysregulation and use of immunosuppressing systemic therapy. Patients with BP and PV have higher potential risk factors for infections secondary to skin alterations, comorbidity and chronic treatment with immunosuppressing agents. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19266DOI Listing

Simultaneous Bullous Pemphigoid and Vitiligo Associated with Adalimumab Therapy in a Patient with Psoriasis Vulgaris.

Indian Dermatol Online J 2020 Mar-Apr;11(2):229-231. Epub 2020 Mar 9.

Department of Dermatology, Hospital General de México, Ciudad de México, CDMX, Mexico.

Antitumor necrosis factors (TNFs) agents are increasingly being used for the effective treatment of diverse diseases. Due to its extensive use and longer duartion of treatment, there are a growing number of reports of the development of autoimmune conditions such as systemic lupus erythematosus, bullous pemphigoid (BP), and vitiligo associated with the use of anti-TNF agents. We describe a patient who developed BP as well as vitiligo after receiving treatment with adalimumab for plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/idoj.IDOJ_53_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7247621PMC

Flame Figures in Linear Immunoglobulin A Bullous Dermatosis Secondary to Parvovirus B19 Infection.

Am J Dermatopathol 2020 May 28. Epub 2020 May 28.

Departments of Dermatology, and.

Flame figures represent a characteristic but nondiagnostic histological finding in eosinophilic dermatoses. Some bullous autoimmune diseases with a predominant eosinophilic infiltrate, such as bullous pemphigoid, pemphigoid gestationis, and pemphigus vegetans, may show them. However, it is rare to find them in predominant neutrophilic bullous dermatoses such as linear immunoglobulin A. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/DAD.0000000000001690DOI Listing

Patients with bullous disorders during COVID-19 period: management and adherence to treatment.

Dermatol Ther 2020 May 26:e13697. Epub 2020 May 26.

Dermatology Unit, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267048PMC

Gastrointestinal involvement of primary skin diseases.

J Eur Acad Dermatol Venereol 2020 May 26. Epub 2020 May 26.

Center for Research & Development, Kaohsiung Municipal Siaogang Hospital, Kaohsiung, Taiwan.

Less is known about gastrointestinal (GI) involvement of primary skin diseases due to the difference in embryology, histology, microbiology and physiology between integument and alimentary tract. Esophagus, following the oropharyngeal mucosa, is the most common GI segment affected by primary skin diseases, especially by eosinophilic esophagitis, lichen planus, and autoimmune bullous dermatoses like pemphigus vulgaris, mucosal membrane pemphigoid and epidermolysis bullosa acquisita. Eosinophilic esophagitis is an emerging chronic atopic disease with esophageal dysfunction as the typical presentation, and esophageal narrowing, rings and stricture as late complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16676DOI Listing

CME Part II: Immune checkpoint inhibitor-related dermatologic adverse events.

J Am Acad Dermatol 2020 May 23. Epub 2020 May 23.

Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; Weill Cornell Medicine, New York, NY. Electronic address:

Immune checkpoint inhibitors (CPI) have emerged as a pillar in the management of advanced malignancies. However, nonspecific immune activation may lead to immune-related adverse events (irAEs), wherein the skin and its appendages are the most frequent targets. Cutaneous irAEs (irCAEs) include a diverse group of inflammatory reactions, with maculopapular rash (MPR), pruritus, and lichenoid dermatitis being the most prevalent subtypes. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.03.132DOI Listing

[Linagliptin and bullous pemphigoid: the story continues].

Semergen 2020 May 22. Epub 2020 May 22.

Centro de Atención Primaria Llefià (Badalona-6), Institut Català de la Salut, Badalona, Barcelona, España.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.semerg.2020.03.005DOI Listing

Bullous pemphigoid associated chronic atrophic gastritis.

Dermatol Ther 2020 May 24:e13671. Epub 2020 May 24.

Department of Dermatology, Allergology and Venereology, Helsinki University Hospital.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13671DOI Listing

A case of drug-induced bullous pemphigoid associated with teriflunomide: A patient with relapsing multiple sclerosis.

Mult Scler Relat Disord 2020 May 15;43:102157. Epub 2020 May 15.

Hacettepe University, Department of Neurology, Hacettepe, 06230, Ankara, Turkey.

Background: There aren't many reported skin changes associated with teriflunomide use in patients with multiple sclerosis (MS) mm Only one life-threatening gross skin change has been reported so far; a patient with toxic epidermal necrolysis. There are also a few case reports about cutaneous adverse effects of teriflunomide, such as eczema, rash and palmar pustular psoriasis.

Methods: We herein report the first case of bullous drug reaction in a patient receiving teriflunomide treatment. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.msard.2020.102157DOI Listing

Missed induced bullous pemphigoid: when the anamnesis is the cure.

J Am Acad Dermatol 2020 May 18. Epub 2020 May 18.

Dermatology, Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.178DOI Listing

Response to: "Missed induced bullous pemphigoid: when the anamnesis is the cure," a Comment on: "Missed Drug-Induced Bullous Pemphigoid Leads to Longer Immunosuppression Than Recognized Cases: A 9-Year Retrospective Review".

J Am Acad Dermatol 2020 May 18. Epub 2020 May 18.

Department of Dermatology, Massachusetts General Hospital; Department of Medicine, Massachusetts General Hospital - Boston, MA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.060DOI Listing

Detection of autoantibodies against alpha-2-macroglobulin-like 1 in paraneoplastic pemphigus sera utilizing novel green fluorescent protein-based immunoassays.

J Dermatol Sci 2020 May 7. Epub 2020 May 7.

Department of Dermatology, Inselspital, Hospital and University of Bern, Bern, Switzerland. Electronic address:

Background: Paraneoplastic pemphigus (PNP) is a devastating autoimmune multiorgan syndrome associated with autoantibodies against several autoantigens, including the alpha-2-macroglobulin-like-1 (A2ML1). A2ML1 is recognized by up to 70 % of PNP sera. The currently recommended techniques for serological diagnosis of PNP are inadequate to detect anti-A2ML1 antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdermsci.2020.04.005DOI Listing

Non-bullous Lichen Planus Pemphigoides: A Case Report.

Acta Derm Venereol 2020 May 28;100(10):adv00156. Epub 2020 May 28.

Department of Dermatology, University of Groningen, University Medical Center Groningen, Hanzeplein 1, NL-9700 RB Groningen, The Netherlands. E-mail:

is missing (Short communication). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2340/00015555-3523DOI Listing

Reply to: "Comment on Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes".

J Am Acad Dermatol 2020 May 14. Epub 2020 May 14.

Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Cutaneous Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.05.023DOI Listing

Case of bullous erythema ab igne mimicking localized bullous pemphigoid.

J Dermatol 2020 May 16. Epub 2020 May 16.

Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15399DOI Listing

Comment on: Bullous pemphigoid after anti-PD-1 therapy: a retrospective case-control study evaluating impact on tumor response and survival outcomes.

J Am Acad Dermatol 2020 May 12. Epub 2020 May 12.

First Dermatology Department, Medical School, Aristotle University of Thessaloniki, Greece.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.174DOI Listing

S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update.

J Dtsch Dermatol Ges 2020 May;18(5):516-526

Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Dermatology, Venereology und Allergy, Allergy Center, Berlin, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ddg.14097DOI Listing

Dermatologic Sequelae Associated with Radiation Therapy.

Am J Clin Dermatol 2020 May 14. Epub 2020 May 14.

Department of Radiation Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Radiation therapy is a mainstay for the treatment of primary malignancies and metastatic disease and is associated with several dermatological adverse events that are underreported in the literature. The objective of this paper was to review the literature regarding cutaneous manifestations associated with radiation therapy in order to promote awareness of the cutaneous radiation therapy-associated adverse effects. This extensive literature review was performed using the Pubmed and Embase databases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-020-00519-xDOI Listing

miR-1291 Functions as a Potential Serum Biomarker for Bullous Pemphigoid.

Dis Markers 2020 11;2020:9505312. Epub 2020 Jan 11.

Department of Dermatology, The First Hospital of China Medical University, National Health Commission Key Laboratory of Immunodermatology, Key Laboratory of Immunodermatology of Ministry of Education, Shenyang, Liaoning, China.

Background: Bullous pemphigoid (BP) is a common T helper 2- (Th2-) dominated autoimmune blistering skin disease with significant mortality. MicroRNAs (miRNAs), which are endogenous noncoding RNA molecules, have been reported to be potential biomarkers for some autoimmune diseases; however, to date, there exist no reports on serum expression profiles of miRNAs in BP patients.

Methods: A RNA quantitative PCR- (qPCR-) based array was conducted on sera from 20 active BP patients and 20 healthy controls for screening of miRNAs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1155/2020/9505312DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7201713PMC
January 2020

Eosinophilic Dermatoses: Recognition and Management.

Am J Clin Dermatol 2020 May 11. Epub 2020 May 11.

Dermatology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.

Eosinophilic dermatoses encompass a broad spectrum of diseases of different etiologies hallmarked by eosinophilic infiltration of the skin and/or mucous membranes, with or without associated blood eosinophilia. The wide range of dermatological manifestations of this spectrum, including nodules and plaques, pustules, blisters, ulcers, and urticarial lesions, is reflected in a non-univocal classification system. We identified six groups of eosinophilic dermatoses based on the predominant anatomic level of involvement: (1) epidermal; (2) of the dermal-epidermal junction; (3) dermal; (4) of the hypodermis and muscle fascia; (5) of the pilosebaceous unit; and (6) vascular/perivascular. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-020-00520-4DOI Listing

A case of infantile bullous pemphigoid successfully treated with compound glycyrrhizin tablets.

Dermatol Ther 2020 May 10:e13550. Epub 2020 May 10.

Department of Dermatovenereology, West China Hospital, Sichuan University, Chengdu, Sichuan Province, China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/dth.13550DOI Listing
May 2020
1.478 Impact Factor

Bullous pemphigoid secondary to pembrolizumab mimicking toxic epidermal necrolysis.

JAAD Case Rep 2020 May 29;6(5):400-402. Epub 2020 Apr 29.

Department of Dermatology, Lewis Katz School of Medicine at Temple University, Philadelphia, Pennsylvania.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.03.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7200194PMC

The association between clinical and laboratory findings of bullous pemphigoid and dipeptidyl peptidase-4 inhibitors in the elderly: a retrospective study.

Croat Med J 2020 Apr;61(2):93-99

Branka Marinović, Department of Dermatolovenereology, University Hospital Centre Zagreb, School of Medicine, University of Zagreb, Šalata 4, 10000 Zagreb, Croatia,

Aim: To evaluate the association between the use of dipeptidyl peptidase-4 inhibitors (DPP4I) and clinical and laboratory findings of bullous pemphigoid (BP) in patients treated at the European Reference Network - Skin Reference Centre in Croatia.

Methods: This retrospective study enrolled 82 patients treated for BP at the Department of Dermatovenereology, University Hospital Center Zagreb from January 2015 to December 2019. Clinical features of BP, presence of comorbidities, and laboratory findings of anti-BP antibodies and eosinophilia were analyzed in three groups of BP patients: 1) diabetes mellitus (DM) type II patients treated with DPP4I, 2) DM type II patients not treated with DPP4I, and 3) non-DM type II patients. Read More

View Article

Download full-text PDF

Source

Mucous membrane pemphigoid and COVID-19 treated with high-dose intravenous immunoglobulins: a case report.

J Dermatolog Treat 2020 May 15:1-2. Epub 2020 May 15.

Department of Dermatology, Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.

This is a report of a case with mucous membrane pemphigoid (MMP) with severe eye involvement and concurrent COVID-19 treated successfully using simultaneous high dose intravenous immunoglobulin (IVIg) and anti-viral treatment as hydroxychloroquine, lopinavir/ritonavir, and ribavirin. He had finished a 2-g cycle of rituximab (RTX) in late January. He was receiving mycophenolate mofetil (MMF) for one month and 30 mg prednisolone for three months until his hospitalization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2020.1764472DOI Listing

Dermatologic toxicities to immune checkpoint inhibitor therapy: A review of histopathologic features.

J Am Acad Dermatol 2020 Apr 28. Epub 2020 Apr 28.

Department of Dermatology University of California Davis, Sacramento, CA;; Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, CA;. Electronic address:

Antineoplastic agents that utilize the immune system have revolutionized cancer treatment. Specifically, implementation of immune checkpoint inhibitors, monoclonal antibodies that block cytotoxic T lymphocyte-associated antigen-4 (CTLA-4), programmed cell death protein 1 (PD-1), or programmed death ligand 1 (PD-L1), show improved and sustained responses in cancer patients. However, these agents are associated with a plethora of adverse events, many manifesting in the skin. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2020.04.105DOI Listing

Exfoliative Erythroderma: An Unusual Presentation of Paraneoplastic Pemphigus Associated with Castleman's Disease.

Case Rep Dermatol 2020 Jan-Apr;12(1):76-81. Epub 2020 Apr 14.

Division of Dermatology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

We report a 23-year-old woman who presented with generalized scaly erythematous rash predominately on the upper trunk and hemorrhagic stomatitis. The histopathologic and immunopathologic findings were consistent with the diagnosis of paraneoplastic pemphigus. Castleman's tumor was diagnosed with computed tomography and exploratory laparotomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000507357DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184796PMC

Pityriasis lichenoides acuta (PLEVA) pemphigoides: A rare bullous variant of PLEVA.

Pediatr Dermatol 2020 Apr 30. Epub 2020 Apr 30.

Division of Paediatric Dermatology, Children's Hospital AUF DER BULT, Hannover, Germany.

Although the clinical presentations of patients with pityriasis lichenoides et varioliformis acuta (PLEVA) may vary, bullae are not usually part of the clinical spectrum. To date, only two other cases of a bullous variant of PLEVA with evidence of autoantibodies against hemidesmosomal antigens have been reported. The term PLEVA pemphigoides was suggested for this unique clinical, pathological and serological combination of both PLEVA and bullous pemphigoid. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/pde.14181DOI Listing

Subepidermal blistering disease acquired autoantibody against laminin 332 during treatment for bullous pemphigoid.

J Dermatol 2020 Apr 30. Epub 2020 Apr 30.

Department of Dermatology, University of Occupational and Environmental Health, Kitakyushu, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15365DOI Listing

Epitope spreading possibly from BP230 to the NC16A domain of BP180 preceding disease progression in bullous pemphigoid.

J Dermatol 2020 Apr 28. Epub 2020 Apr 28.

Department of Dermatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.15362DOI Listing

Detection of circulating anti-skin antibodies by indirect immunofluorescence and by ELISA: a comparative systematic review and meta-analysis.

Clin Chem Lab Med 2020 Apr 25. Epub 2020 Apr 25.

Department of Microbiology and Immunology, Clinical and Diagnostic Immunology, KU Leuven, Leuven, Belgium.

Background Both enzyme-linked immunosorbent assays (ELISAs) and indirect immunofluorescence (IIF) are available for the diagnosis of autoimmune bullous diseases (AIBD). Many studies have reported on the performance of ELISAs and concluded that ELISAs could replace IIF. This study compares the diagnostic accuracy of ELISA and IIF for the detection of autoantibodies to desmoglein 1 (DSG1), desmoglein 3 (DSG3), bullous pemphigoid antigen 2 (BP180) and bullous pemphigoid antigen 1 (BP230) to support the diagnosis of pemphigus vulgaris (PV), pemphigus foliaceus (PF) and bullous pemphigoid (BP). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1515/cclm-2019-1031DOI Listing

Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic.

J Eur Acad Dermatol Venereol 2020 Apr 25. Epub 2020 Apr 25.

Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16525DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7267551PMC

Feasibility and healthcare costs of superpotent topical corticosteroid therapy in bullous pemphigoid: a prospective, observational study in an academic center in France.

Br J Dermatol 2020 Apr 22. Epub 2020 Apr 22.

Department of Dermatology, Reims University Hospital, Reims, France.

Superpotent topical corticosteroids (TCS) were demonstrated to be more effective and safer than high doses of oral corticosteroids to treat extensive bullous pemphigoid (BP). They are proposed as first-line treatment for BP in the Cochrane review and in European guidelines. In France, TCS are the recommended first-line treatment for BP, whatever the severity of the disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.19151DOI Listing

Report of two cases of mucous membrane pemphigoid with frontal fibrosing alopecia: a variant of lichen planus pemphigoides or an incidental finding?

Clin Exp Dermatol 2020 Apr 20. Epub 2020 Apr 20.

Dermatology Department, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, Spain.

Lichen planus pemphigoides (LPP) is a rare autoimmune subepidermal blistering disease characterized by the coexistence of both lichen planus and either bullous pemphigoid or mucous membrane pemphigoid (MMP) features. Frontal fibrosing alopecia (FFA) is a scarring alopecia, generally considered a form of lichen planopilaris. We report two patients with concomitant FFA and MPP. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ced.14248DOI Listing

Localized bullous pemphigoid: a case report.

Ann Transl Med 2020 Mar;8(5):249

Department of Dermatology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100730, China.

Bullous pemphigoid (BP) is a senile autoimmune blistering disease with autoantibodies against the basement membrane. Less than 20 cases of localized BP in young adults have been reported and the understanding of localized BP is very limited. An unusual location of localized BP is here described. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.21037/atm.2020.01.104DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154478PMC

Bullous Pemphigoid in a Patient with Longstanding Hailey-Hailey Disease Complicated by Eczema Herpeticum: Managing the Coexistence of Three Different Blistering Conditions.

J Clin Aesthet Dermatol 2020 Mar 1;13(3):17-19. Epub 2020 Mar 1.

Drs. Calvão da Silva, Vieira, and Brites are with the Dermatology Department at Coimbra University Hospital in Coimbra, Portugal.

Hailey-Hailey disease (HHD), or chronic benign familial pemphigus, is a rare inherited acantholytic dermatosis, characterized by chronic, recurrent vesicles, erosions, and maceration in intertriginous sites. We present a case of a male patient with longstanding HHD who presented with an acute exacerbation characterized by the worsening of pre-existing lesions but also with the appearance of new large, tense bullae on an erythematous base in the areas of the groin (i.e. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159308PMC

Development of Bullous Pemphigoid after Tenckhoff Catheter Placement in a Peritoneal Dialysis Patient.

Authors:
Davide Giunzioni

Case Rep Dermatol 2020 Jan-Apr;12(1):42-46. Epub 2020 Mar 17.

Division of Nephrology, Department of Internal Medicine, Ospedale Regionale di Lugano, Ente Ospedaliero Cantonale, Lugano, Switzerland.

Bullous pemphigoid (BP), a chronic autoimmune subepidermal blistering skin disease, has been described in end-stage renal disease patients requiring dialysis after the placement of an artero-venous fistula. We report a case of a novel onset of BP following a peritoneal dialysis abdominal Tenckhoff catheter placement. The 3-month treatment with systemic doxycycline and topical clobetasol propionate allowed a rapid disappearing of the blisters and left the patient free of symptoms in the follow-up. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000506667DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154232PMC

Immune-Related Oral, Otologic, and Ocular Adverse Events.

Adv Exp Med Biol 2020 ;1244:295-307

Department of Head and Neck Surgery, Division of Surgery, University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Emerging immunotherapy agents, such as immune checkpoint inhibitors, have shown remarkable promise in the treatment of various malignancies. These drugs selectively target different steps in the immune response cascade to upregulate the body's normal response to cancer. Due to the novelty of these therapeutic agents, their toxicity profile is less well understood. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/978-3-030-41008-7_17DOI Listing
January 2020

Prevalence and age distribution of pemphigus and pemphigoid diseases among pediatric patients in Germany.

J Eur Acad Dermatol Venereol 2020 Apr 14. Epub 2020 Apr 14.

Department of Dermatology, University of Lübeck, Lübeck, Germany.

Background: Autoimmune bullous diseases are rare and mostly occur in adults. Several cases and small case series have been described in children but no systematic study about the prevalence of AIBD in children is available.

Patients And Methods: We analysed data of 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.16467DOI Listing

Bullous pemphigoid-like skin rash associated with Rivaroxaban use in a very elderly patient with multimorbidity and chronic kidney disease: A case report.

Clin Case Rep 2020 Apr 26;8(4):725-730. Epub 2020 Feb 26.

Changi General Hospital Singapore Singapore.

Direct oral anticoagulants (DOACs) are increasingly being used in the elderly population in view of its ease of use, efficacy, and favorable side-effect profile compared with the vitamin K antagonists. However, there is a need for increase awareness of well-characterized cases, albeit a small number, of bullous pemphigoid-like skin reactions associated with rivaroxaban. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccr3.2757DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7141729PMC

Recent progresses and perspectives in autoimmune bullous diseases.

J Allergy Clin Immunol 2020 Apr;145(4):1145-1147

Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka, Japan. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.02.020DOI Listing

Autoimmune bullous skin diseases, pemphigus and pemphigoid.

J Allergy Clin Immunol 2020 Apr;145(4):1031-1047

Department of Dermatology, Keio University School of Medicine, Tokyo, Japan; Laboratory for Skin Homeostasis, RIKEN Center for Integrative Medical Science, Kanagawa, Japan. Electronic address:

Autoimmune bullous skin diseases, such as pemphigus and pemphigoid, may enable clarification of the mechanisms of immune regulation in the skin. Pemphigus and pemphigoid are mediated by essentially IgG autoantibodies against structural proteins of the desmosomes at cell-cell junctions and hemidesmosomes at epidermal-dermal junctions, respectively, and are characterized by blisters and erosions in the skin and/or mucous membranes. Intensive investigation over the last 3 decades has identified their target antigens and developed serological diagnostic tools as well as mouse models to help us understand their pathophysiology. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaci.2020.02.013DOI Listing

A case of irritant contact dermatitis and suspected linagliptin-induced koebnerized bullous pemphigoid.

JAAD Case Rep 2020 Apr 25;6(4):316-318. Epub 2020 Mar 25.

Department of Dermatology, University of Missouri-Columbia, Columbia, Missouri.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jdcr.2020.01.011DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7109372PMC

[Epidermolysis bullosa acquisita with Brunsting-Perry type pemphigoid: Diagnostic and therapeutic difficulties].

Ann Dermatol Venereol 2020 Jun - Jul;147(6-7):439-445. Epub 2020 Mar 31.

Service de dermatologie et allergologie, CHRU Nancy, 51, boulevard Albert-Premier, 54000 Nancy, France.

Background: Epidermolysis bullosa acquisita (EBA) is a rare auto-immune blistering disease. We report a case of Brunsting-Perry pemphigoid diagnosed by immunoelectron microscopy (IEM).

Patients And Methods: A 46-year-old man presented very pruriginous vesicles on the face and neck present for 6 years and which were difficult to diagnose and treat. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annder.2020.01.005DOI Listing